We are live on ! Find out more
UBX

Unity Biotechnology

Delisted

UBX was delisted on the 8th of July, 2025.

37 hedge funds and large institutions have $3.1M invested in Unity Biotechnology in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

1.67% less ownership

Funds ownership: 20.54%18.87% (-1.7%)

3% less funds holding

Funds holding: 3837 (-1)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

39% less capital invested

Capital invested by funds: $5.09M → $3.1M (-$1.98M)

Holders
37
Holders Change
-1
Holders Change %
-2.63%
% of All Funds
0.49%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
6
Increased
8
Reduced
7
Closed
5
Calls
$49K
Puts
Net Calls
+$49K
Net Calls Change
-$36K

UBX Hedge Fund Activity: Q4 2024 in Review

37 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2024, worth a combined $3.1M — down 39% from $5.09M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new UBX positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 7 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $43.9K. The largest seller was UBS O'Connor, exiting entirely with an estimated $117K sold.

  • 37 institutional investors held Unity Biotechnology (UBX) as of Q4 2024, down from 38 in Q3 2024.
  • Funds reported $3.1M of Unity Biotechnology stock for Q4 2024, down 39% quarter-over-quarter.
  • 6 funds opened new Unity Biotechnology positions in Q4 2024 and 5 closed out, a net change of +1 holder.
  • The largest Unity Biotechnology buyer in Q4 2024 was Morgan Stanley, an estimated $43.9K added.
  • The largest Unity Biotechnology seller in Q4 2024 was UBS O'Connor, an estimated $117K sold.

Based on aggregated 13F filings for Q4 2024.